HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Icecure Medical (NASDAQ:ICCM) and maintained a $3 price target.
July 02, 2024 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Icecure Medical and maintained a $3 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $3 price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors, suggesting confidence in Icecure Medical's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100